Stefan De Wachter

Stefan De Wachter

Auto-generated profile, based on publicly available information

Stefan De Wachter

Department of Urology, Antwerp University Hospital, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EOEline Oeyen
Eline Oeyen
LHLucien Hoekx
Lucien Hoekx
SWStefan De Wachter
Stefan De Wachter
MBMarcella Baldewijns
Marcella Baldewijns
FAFilip Ameye
Filip Ameye
IMInge Mertens
Inge Mertens
Diagnostic methods currently used for bladder cancer are cystoscopy and urine cytology. Cystoscopy is an invasive tool and has low sensitivity for carcinoma in situ. Urine cytology is non-invasive, is a low-cost method, and has a high specificity but low sensitivity for low-grade urothelial tumors. Despite the search for urinary biomarkers for the early and non-invasive detection of bladder cancer, no biomarkers are used at the present in daily clinical practice. Extracellular vesicles (EVs) have been recently studied as a promising source of biomarkers because of their role in intercellular communication and tumor progression. In this review, we give an overview of Food and Drug Administration (FDA)-approved urine tests to detect bladder cancer and why their use is not widespread in clinical practice. We also include non-FDA approved urinary biomarkers in this review. We describe the role of EVs in bladder cancer and their possible role as biomarkers for the diagnosis and follow-up of bladder cancer patients. We review recently discovered EV-derived biomarkers for the diagnosis of bladder cancer.

1 September 2020 in European Urology Focus
Verified
Journal Article
Closed access
SWStefan De Wachter
Stefan De Wachter
DVDonald Vaganee
Donald Vaganee
Thomas M. KesslerThomas M. Kessler
Thomas M. Kessler

24 December 2019 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
SWStefan De Wachter
Stefan De Wachter
CKCharles H. Knowles
Charles H. Knowles
DEDean S. Elterman
Dean S. Elterman
MKMichael J. Kennelly
Michael J. Kennelly
PLPaul A. Lehur
Paul A. Lehur
PKPhilip E. V. Van Kerrebroeck
Philip E. V. Van Kerrebroeck
Recently rechargeable devices have been introduced for sacral neuromodulation (SNM) with conditional safety for full-body magnetic resonance imaging (MRI). Currently a recharge-free SNM device represents the standard implant; however, it is only approved for MRI head scans. As further new technologies with broader MRI capabilities are emerging, the advantages as well as disadvantages of both rechargeable versus recharge-free devices will be briefly discussed in this commentary from the perspective of patients, healthcare professionals, and providers.

21 October 2021 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
TJTim Jacobs
Tim Jacobs
BGBjörn Geysemans
Björn Geysemans
Guido Van HalGuido Van Hal
Guido Van Hal
IGInge Glazemakers
Inge Glazemakers
KFKristian Fog-Poulsen
Kristian Fog-Poulsen
GWGunter De Win
Gunter De Win
Background: Expanding access to the internet has resulted in more and earlier consumption of online pornography. At the same time, a higher prevalence of erectile dysfunction (ED) among young men is seen. Increased pornography consumption has been suggested as a possible explanation for this rise. Objective: The aim of this study was to better understand associations between problematic pornography consumption (PPC) and ED. Methods: A 118-item survey was published online, and data collection took place between April 2019 and May 2020. Of the 5770 men who responded, the responses from 3419 men between 18 years old and 35 years old were analyzed. The survey used validated questionnaires such as the Cyber Pornography Addiction Test (CYPAT), International Index of Erectile Function (IIEF-5), and Alcohol Use Disorders Identification Test-Concise (AUDIT-C). The estimated amount of porn watching was calculated. Univariable and multivariable analyses were performed. For the multivariable analysis, a logistic regression model using a directed acyclic graph was used. Results: According to their IIEF-5 scores, 21.48% (444/2067) of our sexually active participants (ie, those who attempted penetrative sex in the previous 4 weeks) had some degree of ED. Higher CYPAT scores indicating problematic online pornography consumption resulted in a higher probability of ED, while controlling for covariates. Masturbation frequency seemed not to be a significant factor when assessing ED. Conclusions: This prevalence of ED in young men is alarmingly high, and the results of this study suggest a significant association with PPC. Trial Registration: Research Registry researchregistry5111; https://tinyurl.com/m45mcaa2

1 February 2022 in Expert Review of Medical Devices
Verified
Journal Article
Closed access
STSam Tilborghs
Sam Tilborghs
SWStefan De Wachter
Stefan De Wachter
Sacral Neuromodulation (SNM) is a minimally invasive, guideline-recommended treatment for OAB patients following failure of conventional interventions. Patient selection, lead placement and testing...

28 January 2021 in Neurourology and Urodynamics
Verified
Journal Article
Open access
PDF file
APAndrea Pezzella
Andrea Pezzella
RMRebecca McCrery
Rebecca McCrery
FLFelicia Lane
Felicia Lane
KBKevin Benson
Kevin Benson
CTChris Martin Taylor
Chris Martin Taylor
HGHoward B. Goldman
Howard B. Goldman
Aims: Sacral neuromodulation (SNM) is a guideline‐recommended treatment with proven therapeutic benefit for urinary urgency incontinence (UUI) patients. The Axonics® System is the first Food and Drug Administration‐approved rechargeable SNM system and is designed to deliver therapy for a minimum of 15 years. The ARTISAN‐SNM study was designed to evaluate UUI participants treated with the Axonics System. Two‐year follow‐up results are presented.Methods: One hundred and twenty‐nine UUI participants underwent implantation with the Axonics System. Therapeutic response rate, participant quality of life (QoL), and satisfaction were determined using 3‐day voiding diaries, ICIQ‐OABqol, and satisfaction questionnaires. Participants were considered responders if they had a 50% or greater reduction in UUI episodes post‐treatment. As‐treated and Completers analyses are presented.Results: At 2 years, 93% of the participants (n = 121 Completers at 2 years) were therapy responders, of which 82% achieved ≥ 75% reduction in UUI episodes and 37% were dry (100% reduction). Daily UUI episodes reduced from 5.6 ± 0.3 at baseline to 1.0 ± 0.2 at 2 years. Statistically significant improvements in ICIQ‐OABqol were reported. All participants were able to recharge their device and 94% of participants reported that the recharging frequency and duration were acceptable. Participant demographics nor condition severity were correlated with clinical outcomes or recharging experience. No unanticipated or serious device‐related adverse events occurred.Conclusions: At 2 years, participants treated with the Axonics System demonstrated sustained safety and efficacy, high levels of satisfaction with therapy and recharging. Participant‐related factors were not associated with efficacy or recharging outcomes, indicating the reported results are applicable to a diverse population.